CU23586A1 - Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus - Google Patents

Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus

Info

Publication number
CU23586A1
CU23586A1 CU20050229A CU20050229A CU23586A1 CU 23586 A1 CU23586 A1 CU 23586A1 CU 20050229 A CU20050229 A CU 20050229A CU 20050229 A CU20050229 A CU 20050229A CU 23586 A1 CU23586 A1 CU 23586A1
Authority
CU
Cuba
Prior art keywords
dengue virus
serotypes
therapeutic treatment
proteins
prophlactic
Prior art date
Application number
CU20050229A
Other languages
English (en)
Inventor
Nunez Monica Sarria
Mayora Patricia Grabiela Toledo
Meireles Rolando Paez
Morales Aida Zulueta
Cruz Osmany Guirola
Salazar Noralvis Fleitas
Dunn Alejandro Miguel Martin
Galindo Vivian Huerta
Valdes Jeovanis Gil
Lasa Alexis S Musacchio
Reyes Yuliet Mazola
Cowley Jorge V Gavilondo
Santiago Glay Chinea
Cruz Lisset Hermida
Avila Marta Ayala
Roche Diamile Gonzalez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20050229A priority Critical patent/CU23586A1/es
Priority to US12/094,503 priority patent/US20090312190A1/en
Priority to CA002630629A priority patent/CA2630629A1/en
Priority to ARP060105098A priority patent/AR058215A1/es
Priority to EP06817996A priority patent/EP1958959A2/en
Priority to BRPI0618865-6A priority patent/BRPI0618865A2/pt
Priority to PCT/CU2006/000015 priority patent/WO2007059715A2/es
Priority to JP2008541574A priority patent/JP2009524581A/ja
Priority to KR1020087015049A priority patent/KR20080080137A/ko
Priority to AU2006317350A priority patent/AU2006317350A1/en
Priority to RU2008125077/13A priority patent/RU2008125077A/ru
Priority to CNA2006800513773A priority patent/CN101360758A/zh
Priority to ZA200804874A priority patent/ZA200804874B/xx
Publication of CU23586A1 publication Critical patent/CU23586A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está relacionada con la industria farmacéutica, se describe un área conservada de la superficie de la proteína E, empleable en el desarrollo de moléculas de amplio espectro útiles en la prevención y/o tratamiento de las infecciones por virus dengue 1-4 y otros flavivirus. Además la presente invención se relaciona con proteínas quiméricas para uso en el tratamiento profilático y terapéutico contra los cuatro serotipos del virus de dengue y otros flavivirus.
CU20050229A 2005-11-22 2005-11-22 Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus CU23586A1 (es)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CU20050229A CU23586A1 (es) 2005-11-22 2005-11-22 Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US12/094,503 US20090312190A1 (en) 2005-11-22 2006-11-21 Methods and Proteins for the Prophylactic and/or Therapeutic Treatment of Four Serotypes of Dengue Virus and Other Flaviviruses
CA002630629A CA2630629A1 (en) 2005-11-22 2006-11-21 Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses
ARP060105098A AR058215A1 (es) 2005-11-22 2006-11-21 Metodos y proteinas para el tratamiento profilactico y o terapeutico de los cuatro serotipos del virus de dengue y otros flavivirus
EP06817996A EP1958959A2 (en) 2005-11-22 2006-11-21 Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses
BRPI0618865-6A BRPI0618865A2 (pt) 2005-11-22 2006-11-21 área topográfica e altamente conservada, moléculas, ácido nucleico, proteìna, anticorpos, célula hospedeira, composição farmacêutica, e, método
PCT/CU2006/000015 WO2007059715A2 (es) 2005-11-22 2006-11-21 Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
JP2008541574A JP2009524581A (ja) 2005-11-22 2006-11-21 デング熱ウイルスの４種の血清型及び他のフラビウイルス属の予防的処置及び／又は治療的処置のための方法及びタンパク質
KR1020087015049A KR20080080137A (ko) 2005-11-22 2006-11-21 댕기 바이러스의 네 혈청형 및 그외 플라비바이러스의 예방및/또는 치료를 위한 방법 및 단백질
AU2006317350A AU2006317350A1 (en) 2005-11-22 2006-11-21 Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses
RU2008125077/13A RU2008125077A (ru) 2005-11-22 2006-11-21 Способы и белки для профилактического и/или терапевтического лечения инфекций, вызванных четырьмя серотипами вируса денге и другими флавивирусами
CNA2006800513773A CN101360758A (zh) 2005-11-22 2006-11-21 用于登革病毒的4种血清型和其他黄病毒的预防和/或治疗性治疗的方法和蛋白质
ZA200804874A ZA200804874B (en) 2005-11-22 2008-06-04 Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050229A CU23586A1 (es) 2005-11-22 2005-11-22 Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus

Publications (1)

Publication Number Publication Date
CU23586A1 true CU23586A1 (es) 2010-10-30

Family

ID=38983663

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20050229A CU23586A1 (es) 2005-11-22 2005-11-22 Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus

Country Status (13)

Country Link
US (1) US20090312190A1 (es)
EP (1) EP1958959A2 (es)
JP (1) JP2009524581A (es)
KR (1) KR20080080137A (es)
CN (1) CN101360758A (es)
AR (1) AR058215A1 (es)
AU (1) AU2006317350A1 (es)
BR (1) BRPI0618865A2 (es)
CA (1) CA2630629A1 (es)
CU (1) CU23586A1 (es)
RU (1) RU2008125077A (es)
WO (1) WO2007059715A2 (es)
ZA (1) ZA200804874B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2031528A4 (en) * 2006-05-26 2009-06-17 Univ Kyoto ESTIMATING A PROTEIN-COMPOUND INTERACTION AND RATIONAL DESIGN OF A LIBRARY OF COMPOUNDS BASED ON CHEMICAL GENOMIC INFORMATION
CU20080028A6 (es) 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
CN108610416B (zh) * 2008-10-13 2022-01-14 生物医学研究所 登革热病毒中和抗体及其用途
CN101921310B (zh) * 2009-06-15 2014-03-12 温州医学院 登革病毒特异性hla-a2限制性表位肽及应用
BRPI0904020B8 (pt) * 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
US20130203655A1 (en) * 2010-02-12 2013-08-08 Margaret Kielian Methods for preventing or treating viral infection
WO2011146933A2 (en) * 2010-05-21 2011-11-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Universal dengue virus sequences and methods of use
CN102168058B (zh) * 2010-11-30 2013-01-16 湖南师范大学 一种抗肿瘤靶向工程菌和菌剂及其制备方法
CN102824633A (zh) * 2011-06-16 2012-12-19 中国人民解放军军事医学科学院微生物流行病研究所 一种四价登革病毒亚单位疫苗及其制备方法和应用
KR102181258B1 (ko) 2012-02-16 2020-11-20 브이엘피 테라퓨틱스 엘엘씨 바이러스 유사 입자 조성물
US9821050B2 (en) * 2012-04-02 2017-11-21 The University Of North Carolina At Chapel Hill Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
AU2013295016A1 (en) * 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
MX366886B (es) 2012-08-07 2019-07-30 Massachusetts Inst Technology Anticuerpos anti-virus del dengue y usos de los mismos.
CU24188B1 (es) * 2012-12-27 2016-07-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal contra el virus dengue
CN103116022A (zh) * 2013-01-23 2013-05-22 广西壮族自治区兽医研究所 快速检测猪乙型脑炎抗体试纸条及其制备方法
WO2014180754A1 (en) * 2013-05-07 2014-11-13 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules
ES2745431T3 (es) * 2013-06-26 2020-03-02 Univ North Carolina Chapel Hill Composiciones para vacunas contra el virus del dengue y su uso
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
KR20160119806A (ko) 2014-02-11 2016-10-14 메사추세츠 인스티튜트 오브 테크놀로지 신규한 온전한 범위의 항-뎅기 항체
CN106211773B (zh) 2014-02-11 2021-09-03 威特拉公司 用于登革病毒的抗体分子及其应用
CU20140026A7 (es) * 2014-03-03 2015-11-27 Ct De Ingeniería Genética Y Biotecnología Biocubafarma Péptidos horquilla beta con propiedades antivirales contra el virus dengue
US9969986B2 (en) 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
KR102532832B1 (ko) * 2014-09-11 2023-05-16 브이엘피 테라퓨틱스 인코포레이티드 플라비바이러스 바이러스 유사 입자
RU2017129236A (ru) * 2015-01-26 2019-03-07 Макродженикс, Инк. Мультивалентные молекулы, содержащие dr5-связывающие домены
WO2016130321A1 (en) * 2015-02-09 2016-08-18 Academia Sinica An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017165736A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulation of antibody molecules to dengue virus
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
SG11202005792RA (en) 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
CA3091047A1 (en) * 2018-02-14 2019-08-22 Yale University Compositions for modulation of a trem or treml protein and methods of use
KR102301130B1 (ko) * 2018-12-27 2021-09-15 주식회사 이뮨메드 뎅기출혈열 진단 키트
CN110007067A (zh) * 2019-03-11 2019-07-12 江苏理工学院 一种蛋白质分子对接检测装置
CN110568190A (zh) * 2019-08-30 2019-12-13 深圳国际旅行卫生保健中心 登革热病毒抗原、检测试剂、检测试纸、检测试剂盒及其使用方法
TWI891771B (zh) 2020-04-17 2025-08-01 美商Ｖｌｐ醫療股份有限公司 冠狀病毒疫苗
AU2021264216A1 (en) 2020-04-30 2022-11-10 Vlp Therapeutics, Inc. Cytokine immunotherapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
MY150893A (en) 1996-09-24 2014-03-14 Bavarian Nordic As Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
CU22666A1 (es) * 1996-11-25 2001-04-27 Inst De Medicina Tropical Pedro Kouri Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados
EP0977587B1 (en) 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
WO1999006068A2 (en) 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
AU754386B2 (en) 1997-09-23 2002-11-14 Bavarian Nordic A/S Dengue virus antigens and treatment of dengue fever
AU774045B2 (en) 1998-09-02 2004-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Dengue viruses that are replication defective in mosquitos for use as vaccines
CU23245A1 (es) * 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
WO2004052293A2 (en) * 2002-12-11 2004-06-24 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
WO2005002501A2 (en) * 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
CA2611954C (en) * 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain

Also Published As

Publication number Publication date
ZA200804874B (en) 2009-04-29
CN101360758A (zh) 2009-02-04
AU2006317350A1 (en) 2007-05-31
WO2007059715A3 (es) 2007-10-18
US20090312190A1 (en) 2009-12-17
WO2007059715A8 (es) 2008-02-14
KR20080080137A (ko) 2008-09-02
JP2009524581A (ja) 2009-07-02
AR058215A1 (es) 2008-01-23
BRPI0618865A2 (pt) 2011-09-13
EP1958959A2 (en) 2008-08-20
WO2007059715A2 (es) 2007-05-31
RU2008125077A (ru) 2009-12-27
CA2630629A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
CU23586A1 (es) Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
ECSP066626A (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
BRPI0612309B8 (pt) compostos e composições farmacêuticas antivirais
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
IL257622B (en) Methods and compositions for the treatment of persistent infections
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
NO20085243L (no) Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting
ECSP066791A (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
EA200870164A1 (ru) Лечение вирусного гепатита
ECSP066795A (es) Compuestos novedosos como inhibidores de ns3 serina proteasa del virus de hepatitis c
GT200600317A (es) Inhibidores de la proteasa ns3 del vhc
BRPI0618451A2 (pt) derivados de piridopirazina, seu uso, composição farmacêutica e estojo
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CO6390076A2 (es) Inhibidores de hcv ns5a
CO6390077A2 (es) Inhibidores de hacv ns5a
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
AR058133A1 (es) Metodo de tratamiento y/o prevencion de infecciones en bebes nacidos por cesarea
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
ECSP099385A (es) Formas cristalinas de hemifumarato de aliskiren
MX2017003117A (es) Particula tipo virus de flavivirus.
WO2012061248A8 (en) Novel specific hcv ns3 protease inhibitors
CL2007002370A1 (es) Conjugado que consta de un anticuerpo anti-ccr5 y uno o mas peptidos antifusogenicos; composicion farmaceutica que lo comprende; metodo de preparacion; y su uso para tratar infecciones virales.
BRPI0510016A (pt) vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina